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E-mail address: cmd44@cam.ac.uk (C.M. Dobson).Protein misfolding and aggregation are pathognomic for a number of the most common age-related
degenerative diseases. Great progress has beenmade in studying protein aggregation in the test tube
and also in replicating protein aggregation in vertebrate animal models of these diseases. However,
we argue here that the development and effective integration of emerging techniques such as the
methods of nanoscience and the use of invertebrate models are now providing powerful new oppor-
tunities to advance our current understanding of the fundamental origins of these disorders.
 2009 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
The ability of polypeptide chains in vivo to fold correctly into
their native states with sufﬁcient frequency for them to be able
to execute their functions in a living organism is one of the most
fundamental and remarkable phenomena in biology. Whilst pro-
teins have evolved to contain all the information required to adopt
their correct architecture within their own amino acid sequences,
they are assisted in achieving this fold in vivo by molecular chap-
erones that accelerate and guide this process [1]. Mechanisms such
as the unfolded protein response have also evolved in the cell for
sensing and responding to an excess of misfolded proteins and
for targeting them to be degraded by proteolytic systems such as
the proteosome [2]. However, despite these multiple regulatory
systems and the intrinsic ability of evolved protein sequences to
avoid aggregation, protein misfolding and aggregation neverthe-
less occur, particularly as organisms age, and can cause devastating
diseases [3].
Since the original description of protein deposits in human tis-
sue by Virchow in 1854 (reviewed in [4]), that he termed amyloid
for their apparently tinctorial starch-like properties, a great deal
has been discovered about the origins of such protein deposits,on behalf of the Federation of Euro
–polyacrylamide gel electro-
ta; APP, Amyloid Precursor
olour Coincidence Detection;
sion Chromatography; FRAP,
all Heat shock proteinthe processes by which they are formed and in particular their
association with both the physiology and pathology of organisms
ranging from fungi to humans [5]. As the proteins of which amy-
loid deposits are primarily composed in both neurological condi-
tions such as Alzheimer’s Disease (AD), and non-neuropathic
conditions such as Type II diabetes have been identiﬁed, research-
ers have predominantly adopted two distinct approaches to probe
the origins and consequences of the misfolding and aggregation of
these proteins; the investigation of protein misfolding in vitro
using biophysical techniques and the generation of transgenic
mammalian models replicating the aggregation of proteins associ-
ated with disease in vivo.
In this review we argue that these two approaches have, when
carried out independently, yielded a large number of important in-
sights into the physics and the pathology of protein misfolding.
However, we also discuss how, using new models and methods,
we can bridge the gap between them, enabling us to progress to-
wards translating these insights into meaningful improvements
in the diagnosis and treatment of the many devastating diseases
associated with protein misfolding.
2. Of mice and men with test tubes
The study of protein misfolding and its association with disease
has been transformed by identiﬁcation of the genes whose protein
products are responsible for these diseases. This information has
not only enabled the generation of transgenic models, mainly in
mice, of protein misfolding disorders but also has allowed the pro-
duction of these proteins recombinantly and hence the study ofpean Biochemical Societies.
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to come out of this early period of research were the sheer diver-
sity of the types of proteins that misfold and aggregate into amy-
loid structures (reviewed in [5]) and that the range of proteins
able to convert into the amyloid state is not restricted to those that
have been identiﬁed in disease pathology [6–9]. Subsequently the
formation of amyloid ﬁbrils has also been shown not only to be
associated with pathology but also with functionality in organisms
ranging from Escherichia coli to humans [10,11].
The challenge that arose from these observations was to under-
stand why certain proteins are found in amyloid deposits in vivo
under physiological or pathological conditions, whereas others,
whilst intrinsically capable of aggregating into these amyloid
states do so only under non-native conditions. A number of classi-
cal biophysical studies of the folding and misfolding of proteins
associated with amyloidosis, such as lysozyme and transthyretin
(TTR) [12,13], along with studies of ‘model’ proteins such as acyl-
phosphatase [8] have revealed that aggregation of such folded pro-
teins at detectable rates requires that they become at least partially
destabilised and ‘expose’ aggregation prone sequences that are
capable of self-interaction. In some cases the intrinsic ﬂuctuations
in the native structures provides a mechanism for facilitating such
exposure, but in other more stable proteins a partial unfolding
transition is necessary [14].
A number of amyloid-related diseases are associated with
mutations or abnormal cleavage of the amyloidogenic proteins
and it is clear that these factors act either to destabilise the native
state of the protein itself or to increase the aggregation propensity
of the exposed regions in its polypeptide sequence. Further muta-
genic studies based on these principles have now brought us to the
stage at which we are able to rationalise, with a high degree of con-
ﬁdence, the propensity of different proteins to aggregate into amy-
loid ﬁbrils from a knowledge of their amino acid sequences and the
protection afforded to different regions of a sequence by folding
[15–17].
In parallel with these biochemical attempts to understand the
physicochemical basis of protein misfolding, biomedical scientists
have constructed a wide range of transgenic models that attempt
to capture the major features of both neurological conditions and
systemic amyloidoses. Much attention has been directed at Alzhei-
mer’s Disease as it is the most common neurodegenerative disease
and is becoming increasingly prevalent as our population ages. It is
associated with both classical extracellular amyloid deposits com-
posed of Amyloid b peptides (aggregation prone cleavage frag-
ments of the Amyloid Precursor Protein (APP)), and also
intracellular inclusions in the form of neuroﬁbrillary tangles of
the microtubule associated protein tau (reviewed in [18]). There
is now a wide range of transgenic models of AD based on the over-
expression of various combinations of mutants of either APP, pre-
senilins that form part of the gamma secretase complex which is
responsible for Ab cleavage from APP, or the tau protein itself (re-
viewed in [19]; see www.alzforum.org for an up to date list). Many
of these transgenic animal models successfully reproduce the well
know Ab plaques, and the neuroﬁbrillary tangles of tau that are
found in AD, and so are widely used both in basic research and
in the quest for new treatments.
One of the most important insights that has been gained from
models such as those discussed in the previous paragraph is, how-
ever, the uncertain nature of the relationship between these depos-
its and the pathogenesis of the diseases with which they are
associated. The observation that the Ab plaque burden, for exam-
ple, can be a poor indicator of cognitive decline in these models
[20,21], is consistent with neuropathological studies in humans
[22–24]. Moreover, recent clinical trial results suggest that remov-
ing existing Ab plaques from the brain may not reverse or even halt
cognitive decline [25]. The most commonly postulated, and bestsupported explanations of these observations are now that, con-
trary to the classical ﬁbrillocentric view of amyloid-related dis-
eases, it is the precursors to amyloid formation, so called
preﬁbrillar aggregates or oligomers that are likely to be primarily
responsible for cellular damage in many cases [26]. Furthermore
it has been proposed that these preﬁbrillar aggregates may initiate
a number of cellular signals and responses that may in time be-
come self-perpetuating and independent of the initial misfolded
protein insult [27].
Therefore, as the ﬁeld moves away from the view that this type
of protein misfolding diseases are caused by relatively inert ﬁbril-
lar deposits and towards a view in which these diseases are pri-
marily (but not exclusively) caused by relatively soluble,
dynamic and heterogeneous precursor aggregates that may inter-
act with multiple cellular components, our approaches to tackling
these diseases must adapt accordingly. We require new biophysi-
cal tools to understand the structure and dynamic behaviour of
the various types of ﬁbrillar and preﬁbrillar aggregates and new
models of disease in which we are able to study the consequences
of their formation with greater spatial, temporal and structural
resolution.3. Advances on the biophysical front – new tools for probing
oligomer and ﬁbril formation in vitro
As discussed above, one of the key challenges facing the protein
misfolding ﬁeld in adapting to the prevailing oligomeric view of
diseases such as AD is to be able to describe accurately the struc-
ture and dynamics of the heterogeneous population of species
formed during amyloid aggregation. This step is essential if we
are to determine which oligomeric species of aggregates are
responsible for causing disease and to identify ways of either pre-
venting their formation, enhancing their removal or blocking their
effects.
Amyloid ﬁbrils themselves were distinguished from other ﬁ-
brous structures very early after their discovery by their tinctorial
properties [28]. Consequently dyes such as Congo Red and Thioﬂa-
vin T that bind to amyloid ﬁbrils have been widely used in moni-
toring the kinetics of amyloid aggregation [29]. These methods
have also been complemented by the measurement of the acquisi-
tion of the b-sheet structure that is typical of amyloid ﬁbrils using
spectroscopic techniques such as Circular Dichroism and Fourier
Transform Infrared Spectroscopy [29]. These methods enable a
great deal of information to be garnered on the kinetics of protein
aggregation, and enable us to identify, for example, other mole-
cules that can modulate this process. Nevertheless, these methods
are limited by the resolution with which they can describe the dy-
namic and heterogeneous processes that underlie protein aggrega-
tion, the bulk nature of these measurements, the lack of speciﬁcity
of the dyes in binding and the fact that b-sheet structure is com-
mon to different conformations of aggregates. Consequently it is
difﬁcult to extract information speciﬁcally about oligomer and ﬁ-
bril behaviour from these measurements.
For this reason researchers have sought methods of separately
and accurately probing oligomer formation and ﬁbril growth and
dynamics in vitro. These methods take their inspiration from the
techniques of nanoscience and of single molecule detection. The
key problem in characterising the oligomerisation process that
precedes ﬁbril formation is that this process is very heterogeneous.
Oligomerisation is thought to be initiated by the coalescence of un-
folded, aggregation prone segments of polypeptide chains [30,31].
This process gives rise to oligomeric species with a distribution of
size and conformational properties. During the course of oligomer
formation, the kinetically driven initial state reorganises to give
more thermodynamically stable states, the most highly organised
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(TEM) and Atomic Force Microscopy (AFM) [32,33], and can even
be detected, albeit at quite low temporal and size resolution, using
techniques such as Size Exclusion Chromatography (SEC) [34].
The development of Two Colour Coincidence Detection (TCCD),
can however allow us to overcome these limitations of resolution
and sample heterogeneity. This method has been used successfully
to characterise with single molecule resolution a heterogeneous
population of oligomers, formed by an SH3 domain and to monitor
how it evolves over time [35]. In TCCD a mixture of protein mono-
mers, each labelled with one of two ﬂuorophores that emit light at
different wavelengths, is allowed to aggregate and the resulting
population of aggregates, is diluted to a concentration at which
single particles, oligomers or monomers, can be observed and dis-
tinguished using dual excitation in a confocal laser microscope. The
coincident detection of both emitted wavelengths indicates the
presence of aggregates consisting of more than one molecule and
the intensity of the light emitted and frequency of such coincident
bursts can then be used to determine the size of the aggregates
present, their abundance within the population and even their sta-
bility (Fig. 1). The application of this technique to proteins known
to be involved in protein misfolding diseases has the potential to
unravel much of the confusion that still surrounds the nature of
the oligomerisation of key proteins such as Ab, tau and a synuclein.
Whilst the recent focus of much research into aggregation dis-
orders has been on understanding protein oligomerisation, it is
clear that the process of conversion into ﬁbrils remains crucial to
our understanding of misfolding diseases. This is not only because
the deposition of large quantities of ﬁbrils are very likely to cause
signiﬁcant damage to tissues such as the brain, and indeed are
likely to be the main source of damage in some systemic amyloi-
doses [36], but also as there is now increasing evidence that amy-
loid ﬁbrils are themselves more dynamic than previously
anticipated and may therefore provide an ongoing source of more
toxic ﬁbrillar precursors in vivo [37–39].
Studies of amyloid formation in bulk solution are, however, as
discussed above, complicated by the plethora of species that can
be present during a typical aggregation reaction. We are now, how-
ever, able to measure ﬁbril growth separately from any other com-
peting processes, such as oligomerisation, using a technique
‘borrowed’ from nanoscience, the Quartz Crystal Microbalance
(QCM) (Fig. 2) [40,41]. A QCM is essentially a mass sensor that is
able to detect the elongation of ﬁbrils attached to a layer of gold
deposited on to the surface of a quartz crystal; detection of ﬁbril
growth is possible by measuring the alterations in the resonant fre-
quency of the quartz crystal that occur as the mass of the ﬁbrils at-Fig. 1. Two Colour Coincidence Detection of oligomeric aggregates. (A) Detection of ol
channels show the presence of oligomers (marked as asterisks). (B) Expansion of ﬂuor
oligomers: the monomer ﬂuorescent bursts are not coincident and are much less intense
et al. PNAS 105 (38), 14424–14429.tached to the surface is increased. This method allows not only the
direct determination of growth rates of ﬁbrils but, by scanning the
surface using AFM, it allows the number of ﬁbrils present and their
morphologies to be determined. We have shown that this method
can be used not only to measure the elongation rate with remark-
able accuracy but also to describe unambiguously the inhibition of
ﬁbril elongation by chaperones [42], a phenomenon that is difﬁcult
to detect in bulk solution where chaperones are also known to
interact with a variety of species.
4. Advances on the biological front – improving structural and
temporal resolution of protein aggregation in vivo
Whilst the new biophysical and nanoscience techniques de-
scribed above, along with others being developed, will doubtless
allow us to characterise protein aggregation in the future with
much higher accuracy, and greater structural and temporal resolu-
tion, the problem remains of how to translate these advances into
an improved understanding of the mechanism of the aggregation
of proteins in vivo and its relationship with the pathogenesis of
disease in humans. There is currently something of a chasm be-
tween our knowledge of the types of protein aggregates that can
form in vitro, where the behaviour of even single particles can be
measured on timescales of seconds or less, and those species
formed in vivo where large numbers of aggregates are typically
pooled from tissue samples collected at intervals of days to
months.
The accurate identiﬁcation of speciﬁc conformations of aggre-
gates in vivo and their correlation with cognitive dysfunction, or
other neurological disease-associated phenotypes in humans or in-
deed animal models relies on their extraction from the brain with-
out perturbing their composition. Thus, whilst approaches such as
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE) and Size Exclusion Chromatography allow the deter-
mination of the size of aggregated species that are stable and well
populated, they cannot detect potentially important species that
may not possess these characteristics.
One striking recent example of what can be achieved when new
methods are used to overcome these limitations is the use of Two-
Photon Confocal Microscopy and ﬂuorescent amyloid binding dyes
to monitor the process of Ab plaque formation in a transgenic
mouse model of Alzheimer’s Disease [37]. In this study, daily imag-
ing of the brain in live animals revealed that Ab plaques appear on
unexpectedly short time scales (as little as 24 h) and are remark-
ably stable in size after that time. Studies such as these, which fun-
damentally alter view of protein aggregation kinetics in vivo, showigomer events in PI3–SH3 aggregation. The coincident ﬂuorescent bursts on both
escence bursts in (A). Comparison of the intensity of bursts from monomers and
than those arising from oligomer ﬂuorescence. Figure taken from Orte, Birkett, Clark,
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Fig. 2. Quartz Crystal Microbalance measurement of ﬁbril elongation. (A) Illustration of the principle of ﬁbril growth rate determination by the QCM method. Seed ﬁbrils are
attached to the gold surface that is then passivated using polyethylene glycol (PEG) and a solution of protein molecules is allowed to ﬂow across it. As monomers attach to the
ﬁbril the frequency of the quartz crystal oscillation changes in proportion to the increase in ﬁbril mass. (B) AFM images of the QCM chip before ﬁbril elongation where only
short seed ﬁbrils are present (left) and after ﬁbril elongation where longer and larger ﬁbrils are now visible (right). (C) The effect of a small Heat Shock Protein (sHsp) on ﬁbril
growth is demonstrated by incubating an insulin ﬁbril seeded QCM chip ﬁrst with an insulin solution in buffer (I, green dashed line) and then to a mixture of 0.5:1 molar ratio
of sHsp to insulin (II, red solid line), which inhibits ﬁbril growth. The sHsp binds to ﬁbril elongation sites and signiﬁcantly reduces the rate of further ﬁbril elongation even
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temporal resolution but also of being able to characterise speciﬁc
conformations of aggregates in their natural environments.
Further advances towards achieving in vivo the level of struc-
tural resolution of protein aggregates that can be achieved
in vitro are now being made through the development of confor-
mation speciﬁc binding proteins. The revolutionary observation
was made in 2003 that antibodies can be raised that recognised
particular conformational features associated with speciﬁc types
of aggregates and not just sequence similarity [43]. This develop-
ment made it clear that such tools could, in principle, allow
researchers to overcome the limitations of traditional methods
of extracting and analysing protein aggregates. A range of oligo-
mer and ﬁbril speciﬁc antibodies has now been produced and
has been shown to be a valuable tool for correlating aggregate
conformation with disease phenotypes in vivo. Following on fromthe ﬁrst generation of such antibodies, a new generation of engi-
neered single-chain binding proteins, e.g. camelid antibody do-
mains, afﬁbodies and intrabodies, have now been developed by
several groups to detect speciﬁc misfolded conformations of pro-
teins and aggregates [44,45]. Such single-chain binding proteins
offer potential advantages over conventional antibodies as they
are easily produced, engineered and characterised in vitro and
can be selected from libraries using well-characterised conforma-
tionally homogeneous antigens. These various different types of
conformation-speciﬁc binding proteins have the advantage that
they can be applied in vivo (through injection or direct expres-
sion) to bind to and block the effects of the speciﬁc types of
aggregates to which they bind, allowing the effects of perturbing
particular steps in the aggregation pathway to be determined di-
rectly in living organisms giving both high temporal and struc-
tural resolution [46,47].
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The depth of our understanding of the mechanisms of protein
misfolding and aggregation in vitro depends on our ability to make
very large numbers of measurements rapidly and with increasingly
high structural resolution [48]. If we are to discover whether the
same principles that have been found to govern protein aggrega-
tion in vitro, also govern protein aggregation in vivo we must start
to embrace the use of model organisms that afford us the same
opportunities as those available to biophysicists by test tubes i.e.
transparency, abundance and simplicity. This challenge has been
taken up by a number of groups working on protein misfolding
who now make extensive use of three classical model organisms
Saccharomyces cerevisiae, Caenorhabditis elegans and Drosophila
melanogasterwhich possess between them most of the features re-
quired to act as good ‘living test tubes’ (reviewed in [48]).
We have shown, for example, that Drosophilamake an ideal sys-
tem in which to perform relatively high-throughput mutagenic
analysis of the aggregation of the Ab peptide and its relationship
to neuronal dysfunction. The advantages of short lifespans and
abundance have allowed us to use Drosophila to determine that
the neurodegeneration caused by expressing different mutant Ab
peptides in the brain varies dramatically, but correlates strongly
with their propensities to aggregate into preﬁbrillar species
in vitro (Fig. 3) [49]. Indeed Drosophila are particularly well suited
to studying neurodegeneration as they have a sufﬁciently complex
nervous systems to allow measurements not only of longevity (a
surrogate for neurodegeneration) but also of locomotor behaviour
and even learning and memory [49,50]. The compound eye of Dro-
sophila also provides an externally visible population of neurons
whose degeneration can be easily monitored and which can be
useful in, for example, performing high-throughput genetic
screens.
Whilst such correlative analysis of aggregation and neurode-
generation is very valuable, other physiologically less complex
model organisms, in particular C. elegans, offer better opportunities
to visualise protein aggregation directly in the living organism and
to relate it to behavioural abnormalities and degeneration. Here
the transparency of C. elegans is key, allowing aggregation-prone
polypeptide sequences fused to ﬂuorescent proteins to be readily
visualised by ﬂuorescence microscopy as they aggregate [51].
Differences in the aggregation states of the proteins can even be
determined in situ by examining the mobility of the ﬂuorescent
proteins using techniques such as Fluorescence Recovery AfterPhotobleaching (FRAP) (Fig. 3) [52]. Such studies represent impor-
tant advances as they allow us to monitor protein aggregation as it
occurs in its normal physiological setting whilst simultaneously
assessing the behaviour of an organism for signs of disease-like
phenotypes. Furthermore the easy visualisation of aggregates com-
bined with the available genetic resources for manipulating C. ele-
gans has facilitated a number of genetic screens for modiﬁers of the
protein misfolding and aggregation processes [52].
6. Perspectives
In this review we have highlighted a selection of the new tools
and newmethods now being employed to study protein misfolding
in vitro and in vivo. The key, we believe, to making greater progress
in our goal of understanding the causes and consequences of pro-
tein misfolding lies in ever closer integration of the different ap-
proaches described here, with a particular emphasis on relating
in vivo and in vitro studies. The increasing abundance of tools with
which to monitor the process of aggregation and the behaviour of
aggregates in vivo, in combination with models of protein misfold-
ing and its effects that are sufﬁciently complex to be relevant to
disease and yet simple enough to be amenable to high-throughput
and increasingly sophisticated biophysical and behavioural analy-
sis will, we believe, provide us with unprecedented insights into
the pathogenesis of protein misfolding disorders such as
Alzheimer’s and Parkinson’s Diseases. Furthermore these new
approaches also have the potential to elucidate the underlying
intrinsic and extrinsic factors that regulate the behaviour of
proteins as they strive to fold and function within cells to enable
living organisms to thrive and compete in the process of evolution.
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